Sign in
NetworkOfCare.org
Health Affairs
»
All Tags
»
Pharma
»
Biotech
(
RSS
)
Browse by Tags
Blog Help
Health Affairs
Home
Syndication
RSS for Posts
Atom
RSS for Comments
Recent Posts
Health Affairs’ February Issue: Biomedical Innovation
Health Affairs Briefing: Biomedical Innovation
Sovaldi, Harvoni, And Why It’s Different This Time
Battle Lines Drawn Over Biosimilar Application And Patent Disclosure Process
Adult Conversation On High-Priced Drugs? Don’t Hold Your Breath (But Hang In There) …
Tags
All Categories
Consumers
Costs and Spending
Coverage
Featured
Following the ACA
Health Care Costs
Health Law
Health Reform
Hospitals
Insurance
Insurance and Coverage
Medicaid
Medicaid and CHIP
Medicare
Payment
Payment Policy
Physicians
Policy
Politics
Population Health
Public Health
Quality
Spending
States
View more
Archives
October 2017 (46)
September 2017 (53)
August 2017 (58)
July 2017 (55)
June 2017 (73)
May 2017 (58)
April 2017 (53)
March 2017 (66)
February 2017 (54)
January 2017 (57)
December 2016 (50)
November 2016 (35)
October 2016 (46)
September 2016 (50)
August 2016 (41)
July 2016 (41)
June 2016 (62)
May 2016 (47)
April 2016 (45)
March 2016 (84)
February 2016 (59)
January 2016 (44)
December 2015 (45)
November 2015 (45)
October 2015 (57)
September 2015 (59)
August 2015 (53)
July 2015 (65)
June 2015 (68)
May 2015 (51)
April 2015 (64)
March 2015 (49)
February 2015 (46)
January 2015 (37)
December 2014 (49)
November 2014 (54)
October 2014 (44)
September 2014 (51)
August 2014 (42)
July 2014 (44)
June 2014 (42)
May 2014 (40)
April 2014 (47)
March 2014 (49)
February 2014 (47)
January 2014 (43)
December 2013 (32)
November 2013 (26)
October 2013 (32)
September 2013 (38)
August 2013 (31)
July 2013 (32)
June 2013 (32)
May 2013 (37)
April 2013 (32)
March 2013 (30)
February 2013 (35)
January 2013 (26)
December 2012 (29)
November 2012 (28)
October 2012 (28)
September 2012 (31)
August 2012 (29)
July 2012 (27)
June 2012 (39)
May 2012 (29)
April 2012 (33)
March 2012 (43)
February 2012 (29)
January 2012 (25)
December 2011 (31)
November 2011 (29)
October 2011 (26)
September 2011 (34)
August 2011 (26)
July 2011 (29)
June 2011 (33)
May 2011 (34)
April 2011 (30)
March 2011 (34)
February 2011 (31)
January 2011 (24)
December 2010 (18)
November 2010 (25)
October 2010 (24)
September 2010 (26)
August 2010 (31)
July 2010 (27)
June 2010 (23)
May 2010 (20)
April 2010 (20)
March 2010 (32)
February 2010 (23)
January 2010 (24)
December 2009 (21)
November 2009 (23)
October 2009 (28)
September 2009 (3)
Access
All Categories
Bioethics
Blog
Business of Health Care
Children
Chronic Care
Competition
Consumers
Cost
drug
Effectiveness
HA_BiomedInnovation
Health Care Costs
Health Law
Health Reform
Hospitals
Innovation
Insurance
Medicare
part d
Payment
Physicians
Policy
pricing
Research
Science and Health
Spending
States
Technology
Uncategorized
Health Affairs’ February Issue: Biomedical Innovation
The February issue of Health Affairs includes a number of studies examining issues pertaining to biomedical innovation. Some of the subjects covered: how declining economic returns for new drugs may affect future investments, the changing landscape of...
Published
Mon, Feb 02 2015 1:05 PM
by
Health Affairs Blog
Filed under:
All Categories
,
Policy
,
Medicare
,
Pharma
,
Innovation
,
Technology
,
Biotech
,
Science and Health
,
Research
,
HA_BiomedInnovation
Health Affairs Briefing: Biomedical Innovation
Biomedical innovation lengthens and enriches our lives through breakthroughs in medications and care, but it is has also been the leading source of health care cost growth over the past few decades. The upcoming February 2015 thematic issue of Health...
Published
Tue, Jan 01 2015 1:15 PM
by
Health Affairs Blog
Filed under:
All Categories
,
Policy
,
Health Care Costs
,
Pharma
,
Innovation
,
Technology
,
Biotech
,
Science and Health
,
Research
Sovaldi, Harvoni, And Why It’s Different This Time
With the Food and Drug Administration (FDA)’s approval of Harvoni, the successor to Gilead Science’s Sovaldi, the alarm bells have officially rung on breakthrough hepatitis C treatments. One can’t open a newspaper or scan a Twitter feed without stumbling...
Published
Fri, Nov 11 2014 11:18 AM
by
Health Affairs Blog
Filed under:
All Categories
,
Health Care Costs
,
Spending
,
Access
,
Bioethics
,
Pharma
,
Biotech
,
Business of Health Care
Battle Lines Drawn Over Biosimilar Application And Patent Disclosure Process
The Biosimilars Price Competition and Innovation Act of 2009 (BPCIA) introduced a long-awaited, and highly-supported, abbreviated route to market for “biosimilar” and “interchangeable” biologic products. The goal was to create incentives for development...
Published
Mon, Nov 11 2014 6:00 AM
by
Health Affairs Blog
Filed under:
All Categories
,
Bioethics
,
Pharma
,
Biotech
,
Science and Health
,
Research
Adult Conversation On High-Priced Drugs? Don’t Hold Your Breath (But Hang In There) …
The benevolent identity of the health care enterprise tends to moderate disagreements and keep them under a big tent of shared goals. In the case of very high prices for powerful new drugs, however, the commons gets stretched painfully thin. Drug companies...
Published
Mon, Oct 10 2014 12:42 PM
by
Health Affairs Blog
Filed under:
All Categories
,
Consumers
,
Insurance
,
Chronic Care
,
Health Care Costs
,
Pharma
,
Biotech
,
Business of Health Care
Health Affairs October Issue: Specialty Drugs — Cost, Impact, And Value
The October issue of Health Affairs , released today, includes a number of studies looking at the high costs associated with today’s increasingly prevalent specialty drugs. Other subjects covered in the issue: an assessment of whether some hospitals may...
Published
Mon, Oct 10 2014 1:02 PM
by
Health Affairs Blog
Filed under:
All Categories
,
Consumers
,
Physicians
,
Health Care Costs
,
Pharma
,
Hospitals
,
Biotech
Reminder: Health Affairs Briefing: Specialty Pharmaceuticals
We live in an era of specialty pharmaceuticals -- drugs typically used to treat chronic, serious or life threatening conditions such as cancer, rheumatoid arthritis, growth hormone deficiency, and multiple sclerosis. Their cost is often much higher than...
Published
Fri, Oct 10 2014 8:48 AM
by
Health Affairs Blog
Filed under:
All Categories
,
Policy
,
Health Care Costs
,
Spending
,
Bioethics
,
Pharma
,
Hospitals
,
Innovation
,
Biotech
Rescue Me: The Challenge Of Compassionate Use In The Social Media Era
The Development of Brincidofovir and its Possible Use to Treat Josh Hardy Last March 4, seven-year old Josh Hardy lay critically ill in the intensive care unit at St Jude Children’s Hospital in Memphis, Tennessee with a life-threatening adenovirus infection...
Published
Wed, Aug 08 2014 9:29 AM
by
Health Affairs Blog
Filed under:
All Categories
,
Consumers
,
Policy
,
Access
,
Bioethics
,
Pharma
,
Technology
,
Biotech
,
Research
Accelerating Medicines Partnership: A New Public-Private Collaboration For Drug Discovery
Editor's note: This post is also coauthored by Yongtian Tan and is published in conjunction with the April issue of Health Affairs , which explores the many subjects raised by Alzheimer's disease including a new public-private research collaboration...
Published
Tue, Apr 04 2014 6:26 AM
by
Health Affairs Blog
Filed under:
All Categories
,
Pharma
,
Biotech
,
Research
Health Policy Brief: Biosimilars
A new Health Policy Brief from Health Affairs and the Robert Wood Johnson Foundation explains key elements of the Biologics Price Competition and Innovation Act (BPCIA), a provision of the Affordable Care Act. The BPCIA authorizes the Food and Drug Administration...
Published
Thu, Oct 10 2013 11:49 AM
by
Health Affairs Blog
Filed under:
All Categories
,
Health Reform
,
States
,
Competition
,
Pharma
,
Health Law
,
Innovation
,
Biotech
,
Business of Health Care
System Transformation Intensifies Demand for Evidence: The Trust Conundrum
Although we have witnessed historic lows in the rate of growth of healthcare spending, the implementation of the Affordable Care Act and secular trends have created fundamentally new dynamics in how providers, clinicians, and patients are exposed to the...
Published
Tue, Sep 09 2013 10:20 AM
by
Health Affairs Blog
Filed under:
All Categories
,
Health Reform
,
Policy
,
Payment
,
Pharma
,
Health Law
,
Technology
,
Effectiveness
,
Biotech
,
Research
Adolescents And Young Adults: Bringing A Neglected Group Into Cancer Research
“A child is not a small adult,” but an adolescent is not a large child. Adult oncologists, reluctant to care for cancer patients under the age of 16, believe that adolescent and young adult (AYA) cancer patients should be within their purview. We...
Published
Fri, Jan 01 2012 9:16 AM
by
Health Affairs Blog
Filed under:
Bioethics
,
Pharma
,
Children
,
Biotech
,
Research
Medicare Part D drug pricing
Reducing Medicare Part D drug prices requires careful tools, not simply the power to negotiate Read More...
Published
Thu, Apr 04 2010 11:55 AM
by
Health Affairs Blog
Filed under:
Blog
,
Policy
,
Health Care Costs
,
Uncategorized
,
Medicare
,
Pharma
,
Cost
,
Health Law
,
part d
,
Biotech
,
drug
,
pricing